AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31917441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab, 0.5 mg, in a Treat-and-Extend (T&E) regimen
Number of subjects: 580
Study 31917441 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal ranibizumab, 0.5 mg, in monthly dosing regimen
Number of subjects: 580
Study 31917441 — intervention group
Group type: EXPERIMENTAL
Intervention: T&E regimen
Number of subjects: 580
Study 31917441 — intervention group
Group type: COMPARATOR
Intervention: Monthly regimen
Number of subjects: 580
Study 29459994 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser enucleation of the prostate (DiLEP)
Number of subjects: 114
Study 29459994 — intervention group
Group type: COMPARATOR
Intervention: Bipolar endoscopic enucleation of the prostate (BEEP)
Number of subjects: 114
Study 28394249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 465
Study 28394249 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychoanalytic psychotherapy (STPP)
Number of subjects: 465
Study 28394249 — intervention group
Group type: COMPARATOR
Intervention: Brief psychosocial intervention (BPI)
Number of subjects: 465
Study 25778541 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape/blueberry juice (841 mg ACN/litre)
Number of subjects: 10
Study 25778541 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape/blueberry smoothie (983 mg ACN/litre)
Number of subjects: 10
Study 25778541 — intervention group
Group type: COMPARATOR
Intervention: Grape/blueberry juice
Number of subjects: 10
Study 25778541 — intervention group
Group type: COMPARATOR
Intervention: Grape/blueberry smoothie
Number of subjects: 10
Study 25778541 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro absorption of grape/blueberry extract
Number of subjects: 10
Study 24337060 — intervention group
Group type: EXPERIMENTAL
Intervention: Online version of the Female Sexual Function Index (FSFI)
Number of subjects: 273
Study 24337060 — intervention group
Group type: COMPARATOR
Intervention: Traditional pen and paper version of the FSFI
Number of subjects: 273
Study 24337060 — intervention group
Group type: EXPERIMENTAL
Intervention: Online version of the FSFI (G-pp/ol after 15 days)
Number of subjects: 273
Study 24337060 — intervention group
Group type: COMPARATOR
Intervention: Traditional pen and paper version of the FSFI (G-ol/pp after 15 days)
Number of subjects: 273
Study 20543220 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized rehabilitation protocol with physiotherapists trained in a clinical rehabilitation model
Number of subjects: 40
Study 20543220 — intervention group
Group type: COMPARATOR
Intervention: Standardized rehabilitation protocol without self-efficacy scores provided to physiotherapists
Number of subjects: 40
Study 20543220 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 20543220 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical rehabilitation model with strategies to enhance self-efficacy
Number of subjects: 40
Study 18753292 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg infusion)
Number of subjects: 22
Study 18753292 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 22
Study 16551930 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CFNB)
Number of subjects: 36
Study 14556729 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofibre(R) dressing
Number of subjects: 80
Study 14556729 — intervention group
Group type: COMPARATOR
Intervention: Glycerol preserved allograft skin
Number of subjects: 80
Study 10917403 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg FLX daily
Number of subjects: 70
Study 10917403 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg FLX weekly
Number of subjects: 70
Study 10917403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 8645377 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic maternal cocaine use (MCU+) with positive neonatal urine cocaine test (NUC+)
Number of subjects: 87
Study 8645377 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic maternal cocaine use (MCU+) with negative neonatal urine cocaine test (NUC-)
Number of subjects: 87
Study 8645377 — intervention group
Group type: COMPARATOR
Intervention: No chronic maternal cocaine use (MCU-) and negative neonatal urine cocaine test (NUC-)
Number of subjects: 87
Study 8645377 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitor assessment
Number of subjects: 87
Study 1626677 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose morphine combined with bupivacaine for intercostal nerve blocks
Number of subjects: 0
Study 1626677 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone (control)
Number of subjects: 0
Study 6386330 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram treatment
Number of subjects: 0
Study 6386330 — intervention group
Group type: COMPARATOR
Intervention: Control group (no disulfiram, told they are not receiving disulfiram)
Number of subjects: 0
Study 6386330 — intervention group
Group type: COMPARATOR
Intervention: Control group (given disulfiram, told they are receiving disulfiram)
Number of subjects: 0
Study 31793645 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrivida (fortified food)
Number of subjects: 54
Study 31793645 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrisano (fortified food)
Number of subjects: 54
Study 31793645 — intervention group
Group type: EXPERIMENTAL
Intervention: Syrup (alternative supplement for children)
Number of subjects: 54
Study 31793645 — intervention group
Group type: EXPERIMENTAL
Intervention: MNP-C (micronutrient powders for children)
Number of subjects: 54
Study 31793645 — intervention group
Group type: EXPERIMENTAL
Intervention: MNP-W (micronutrient powders for women)
Number of subjects: 54
Study 31793645 — intervention group
Group type: EXPERIMENTAL
Intervention: Any supplement (general outcome)
Number of subjects: 54
Study 29195851 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior referencing (PR) system
Number of subjects: 211
Study 29195851 — intervention group
Group type: COMPARATOR
Intervention: Anterior referencing (AR) system
Number of subjects: 211
Study 29195851 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 211
Study 26649466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue exposure intervention
Number of subjects: 0
Study 26649466 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0
Study 24499750 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision mini-sling
Number of subjects: 130
Study 24499750 — intervention group
Group type: COMPARATOR
Intervention: Transobturator sling
Number of subjects: 130
Study 22609816 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole (modal dose 16 mg/day)
Number of subjects: 294
Study 20555277 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing long jump (SLJ)
Number of subjects: 94
Study 20555277 — intervention group
Group type: COMPARATOR
Intervention: Other lower body muscular strength tests (vertical jump, squat jump, countermovement jump)
Number of subjects: 94
Study 20555277 — intervention group
Group type: COMPARATOR
Intervention: Upper body muscular strength tests (throw basketball, push-ups, isometric strength exercises)
Number of subjects: 94
Study 17437689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 0
Study 15758010 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide and radiotherapy
Number of subjects: 206
Study 15758010 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 206
Study 12098155 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted movement training (24 sessions of 1 hour over 2 months)
Number of subjects: 27
Study 12098155 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy techniques (neurodevelopmental therapy with 5 minutes of robot exposure per session)
Number of subjects: 27
Study 10081851 — intervention group
Group type: EXPERIMENTAL
Intervention: Single immediate instillation of 30 mg mitomycin C
Number of subjects: 131
Study 10081851 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 131
Study 7569360 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 198
Study 7569360 — intervention group
Group type: COMPARATOR
Intervention: Animal insulin
Number of subjects: 198
Study 2287773 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-a-day amikacin (14 mg/kg per day)
Number of subjects: 78
Study 2287773 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-a-day netilmicin (6.6 mg/kg per day)
Number of subjects: 78
Study 2287773 — intervention group
Group type: COMPARATOR
Intervention: Conventional schedule amikacin (cs)
Number of subjects: 78
Study 2287773 — intervention group
Group type: COMPARATOR
Intervention: Conventional schedule netilmicin (cs)
Number of subjects: 78
Study 6795047 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxycholecalciferol (1,25(OH)2D3) alone in a daily dose of 0.25 micrograms
Number of subjects: 84
Study 6795047 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogens/gestagen alone or combined with 1,25(OH)2D3
Number of subjects: 84
Study 6795047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 29893798 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin (200 mg once daily)
Number of subjects: 600
Study 29893798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 28487415 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet CPAP
Number of subjects: 0
Study 28487415 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 0
Study 28487415 — intervention group
Group type: COMPARATOR
Intervention: Standard therapeutic pharmaceutical protocols (Control)
Number of subjects: 0
Study 26377909 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% dextrose gel (200 mg/kg)
Number of subjects: 2129
Study 26377909 — intervention group
Group type: COMPARATOR
Intervention: 2% hydroxymethylcellulose placebo
Number of subjects: 2129
Study 23587733 — intervention group
Group type: EXPERIMENTAL
Intervention: teduglutide (0.05 mg/kg/day s.c.)
Number of subjects: 86
Study 23587733 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 86
Study 21863254 — intervention group
Group type: EXPERIMENTAL
Intervention: First eye surgery under topical anesthesia
Number of subjects: 73
Study 21863254 — intervention group
Group type: EXPERIMENTAL
Intervention: Second eye surgery under topical anesthesia
Number of subjects: 73
Study 21863254 — intervention group
Group type: COMPARATOR
Intervention: First eye surgery
Number of subjects: 73
Study 21863254 — intervention group
Group type: COMPARATOR
Intervention: Second eye surgery
Number of subjects: 73
Study 21863254 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between VAS scores of first and second procedures
Number of subjects: 73
Study 18987127 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol titrated to achieve a heart rate of <100 bpm followed by ibutilide (IB) co-administration
Number of subjects: 90
Study 18987127 — intervention group
Group type: COMPARATOR
Intervention: Ibutilide (IB) as monotherapy
Number of subjects: 90
Study 18987127 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol and IB combination therapy
Number of subjects: 90
Study 17287476 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus placebo
Number of subjects: 626
Study 17287476 — intervention group
Group type: COMPARATOR
Intervention: Extended-release metformin plus placebo
Number of subjects: 626
Study 17287476 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metformin and clomiphene
Number of subjects: 626
Study 17287476 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 626
Study 17287476 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 626
Study 17287476 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 626
Study 15377967 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill (OCP) users
Number of subjects: 127
Study 15377967 — intervention group
Group type: COMPARATOR
Intervention: Nonusers
Number of subjects: 127
Study 15377967 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-menstruating OCP users
Number of subjects: 127
Study 11216737 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive direct coronary artery bypass grafting (MIDCABG)
Number of subjects: 58
Study 11216737 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating heart surgery
Number of subjects: 58
Study 11216737 — intervention group
Group type: COMPARATOR
Intervention: Standard CABG
Number of subjects: 58
Study 11216737 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 58
Study 9474310 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-Tenon's anaesthesia
Number of subjects: 129
Study 9474310 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar anaesthesia
Number of subjects: 129
Study 7959185 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg atenolol (a selective beta 1 antagonist)
Number of subjects: 10
Study 7959185 — intervention group
Group type: COMPARATOR
Intervention: Matched dummy tablets (control)
Number of subjects: 10
Study 3610510 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine (0.3% concentration)
Number of subjects: 40
Study 3610510 — intervention group
Group type: COMPARATOR
Intervention: Similar solution without the active substance (Control)
Number of subjects: 40
Study 28927636 — intervention group
Group type: EXPERIMENTAL
Intervention: Upstream dual anti-platelet therapy (DAT) with aspirin and clopidogrel without intra-procedural anti-coagulation (Group 1)
Number of subjects: 200
Study 28927636 — intervention group
Group type: COMPARATOR
Intervention: Upstream dual anti-platelet therapy (DAT) with aspirin and clopidogrel plus intra-procedural bivalirudin (Group 2)
Number of subjects: 200
Study 26874946 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (10 mg, three times daily from 2 days before to 3 days after procedure)
Number of subjects: 240
Study 26874946 — intervention group
Group type: COMPARATOR
Intervention: Control (matching placebo)
Number of subjects: 240
Study 26874946 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 240
Study 26874946 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 240
Study 23644602 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis CD2 lozenges
Number of subjects: 191
Study 23644602 — intervention group
Group type: COMPARATOR
Intervention: No L. brevis lozenge (control)
Number of subjects: 191
Study 23529727 — intervention group
Group type: EXPERIMENTAL
Intervention: fast-release GSK1322322
Number of subjects: 20
Study 23529727 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1322322 with high-fat meal
Number of subjects: 20
Study 23529727 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1322322 with H2 blocker
Number of subjects: 20
Study 23529727 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1322322 with H2 blocker plus vitamin C
Number of subjects: 20
Study 19923796 — intervention group
Group type: EXPERIMENTAL
Intervention: GLY-230 (250, 500, or 750 mg daily for 14 days)
Number of subjects: 21
Study 19923796 — intervention group
Group type: EXPERIMENTAL
Intervention: GLY-230
Number of subjects: 21
Study 19923796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 18248644 — intervention group
Group type: COMPARATOR
Intervention: Oral 17-beta-oestradiol (E(2)) 1, 2 and 4 mg daily in a cyclical formulation for 12 weeks
Number of subjects: 125
Study 18248644 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive pill (OCP)
Number of subjects: 125
Study 16758262 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg once daily for 5 days)
Number of subjects: 10
Study 14558184 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 8677
Study 14558184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 8677
Study 14558184 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 8677
Study 14558184 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant use of medication contra-indicated in the drugs' labeling
Number of subjects: 8677
Study 14558184 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing number of other concomitant medications
Number of subjects: 8677
Study 14558184 — intervention group
Group type: EXPERIMENTAL
Intervention: History of previous GI disorder
Number of subjects: 8677
Study 14558184 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 8677
Study 14558184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen vs Paracetamol for GI SAE
Number of subjects: 8677
Study 11352967 — intervention group
Group type: EXPERIMENTAL
Intervention: Black cohosh
Number of subjects: 85
Study 11352967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 9424602 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA (recombinant plasminogen activator)
Number of subjects: 0
Study 9424602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8199751 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg pantoprazole
Number of subjects: 12
Study 8199751 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg pantoprazole
Number of subjects: 12
Study 8199751 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole
Number of subjects: 12
Study 8199751 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg pantoprazole
Number of subjects: 12
Study 2439833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg orally)
Number of subjects: 17
Study 2439833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2439833 — intervention group
Group type: COMPARATOR
Intervention: Aprotinin infusion
Number of subjects: 17
Study 31921328 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding counselling based on Carl Rogers' Centred‐Client Theory, performed during the last month of pregnancy, 24 hours after delivery, and during early infancy (1 and 3 months postpartum).
Number of subjects: 0
Study 31921328 — intervention group
Group type: COMPARATOR
Intervention: Standard management (control group).
Number of subjects: 0
Study 29206274 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention programme (n = 141)
Number of subjects: 284
Study 29206274 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that work was cause of the pain
Number of subjects: 284
Study 29206274 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety and depression
Number of subjects: 284
Study 29206274 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between multidisciplinary intervention and perceived support at work
Number of subjects: 284
Study 29206274 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of sick leave
Number of subjects: 284
Study 28389864 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ injury prevention program
Number of subjects: 136
Study 26695176 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led lifestyle program consisting of four to five individual consultations over one year
Number of subjects: 366
Study 26695176 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 366
Study 23037617 — intervention group
Group type: COMPARATOR
Intervention: Strength and endurance (SE) group
Number of subjects: 20
Study 23037617 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength, endurance, and maximal‐effort cycling (SEC) group
Number of subjects: 20
Study 21245882 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium fortified laddoo containing 405 mg calcium per day and a monthly vitamin D supplement of 30,000 IU
Number of subjects: 60
Study 21245882 — intervention group
Group type: COMPARATOR
Intervention: Non-fortified laddoo containing 156 mg of indigenous calcium and a monthly vitamin D supplement of 30,000 IU
Number of subjects: 60
Study 18802818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonification pulse rate set to 60 pulses per minute
Number of subjects: 0
Study 18802818 — intervention group
Group type: COMPARATOR
Intervention: Variable sonification pulse rates and sensor reliability
Number of subjects: 0
Study 16409195 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite immunotherapy with Alutard SQ (Dermatophagoides pteronyssinus extract) for 52 weeks
Number of subjects: 132
Study 16409195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 12627930 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 80 mg administered after consumption of a standardized continental breakfast
Number of subjects: 16
Study 12627930 — intervention group
Group type: COMPARATOR
Intervention: Testosterone undecanoate 80 mg administered during a fasting period
Number of subjects: 16
Study 10846306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy for adolescents (CBGT‐A)
Number of subjects: 35
Study 10846306 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 35
Study 9113218 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence goal
Number of subjects: 106
Study 9113218 — intervention group
Group type: COMPARATOR
Intervention: Moderate drinking goal
Number of subjects: 106
Study 31184506 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratography (K5M, Oculus, Germany)
Number of subjects: 41
Study 31184506 — intervention group
Group type: COMPARATOR
Intervention: Swept-source OCT (Casia SS-1000, Tomey Corp, Japan)
Number of subjects: 41
Study 31184506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescein instillation (moistened fluorescein strip)
Number of subjects: 41
Study 31184506 — intervention group
Group type: COMPARATOR
Intervention: Conjunctival touch (inferior bulbar or inferior palpebral)
Number of subjects: 41
Study 28198032 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.5 mg/kg, IV, three times a day)
Number of subjects: 32
Study 28198032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (0.5 mg/kg, IV, three times a day)
Number of subjects: 32
Study 28198032 — intervention group
Group type: EXPERIMENTAL
Intervention: Maropitant (1 mg/kg, SC, once a day)
Number of subjects: 32